ClinicalTrials.gg
CompletedNCT05969223UnlIMMitedUpdated Feb 24, 2026Results posted

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

A Phase 4 interventional study of Risankizumab and Placebo for Risankizumab in Genital Psoriasis and Scalp Psoriasis, sponsored by AbbVie. Completed at 38 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by AbbVie · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
12th of 30
214 · median 162
Started
2023
the only one that year
Phase 4
7 of 30
1 open now
Registered
28th of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one is the 12th largest by enrollment, is the only one that started in 2023, is one of 7 in phase 4, and was the 28th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is in adult participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Adverse events and change in disease signs and symptoms will be monitored.

Risankizumab (Skyrizi) is a drug being studied for the treatment of moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Approximately 200 participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis will be enrolled across approximately 45 sites globally.

The study will be broken up into 2 studies by disease location, participants with moderate to severe genital psoriasis (Study-G) and moderate to severe scalp psoriasis (Study-S). In both studies participants will receive subcutaneous (SC) injections of risankizumab during the 52 week treatment period, or SC injections of placebo risankizumab during the 16 week treatment period followed by SC injections of risankizumab during the 36 week treatment period, with an 8-week follow-up period after the 52 week treatment period.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Read the detailed description

Safety and efficacy data through 22 January 2025 are included in the interim analysis, which was conducted after all participants completed Week 16 of Study-G or Study-S in Period A.

03

Conditions studied

  • Genital Psoriasis
  • Scalp Psoriasis

Browse trials for

Keywords

  • Genital Psoriasis
  • Scalp Psoriasis
  • Plaque Psoriasis
  • Psoriasis
  • ABBV066
  • Skyrizi
  • Risankizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have clinical diagnosis of chronic plaque psoriasis with or without psoriatic arthritis for at least 6 months before the baseline visit.
  • Must have a current diagnosis of moderate to severe genital psoriasis (Study-G) defined as static Physician Global Assessment of Genitalia (sPGA-G) ≥ 3 or moderate to severe scalp psoriasis (Study-S) defined as Psoriasis Scalp Severity Index (PSSI) >= 12, scalp Investigator Global Assessment (IGA) >= 3, and >= 30% of the scalp affected.
  • Must have body surface area (BSA) ≥ 1% with at least 60% of subjects having BSA ≥ 10%; sPGA ≥ 3; inadequate control of psoriasis and/or intolerance to topical treatment, phototherapy and/or systemic therapy; and be candidates for systemic therapy or phototherapy as assessed by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Had previous exposure to IL-23 inhibitors including but not limited to guselkumab, tildrakizumab, ustekinumab, mirikizumab, or risankizumab.
  • History of an allergic reaction or significant sensitivity to constituents of the study drug (and its ) and/or other products in the same class.
  • Non-plaque forms of psoriasis or other active skin disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
214 participants (actual)

Study arms

  • Placebo comparator
    Study-G Placebo (Period A)

    Participants with moderate to severe genital psoriasis received placebo for risankizumab subcutaneously at Weeks 0 and 4 during Period A.

    Drug: Placebo for Risankizumab

  • Experimental
    Study-G Risankizumab (Period A)

    Participants with moderate to severe genital psoriasis received 150 mg of risankizumab subcutaneously at Weeks 0 and 4 during Period A.

    Drug: Risankizumab

  • Placebo comparator
    Study-S Placebo (Period A)

    Participants with moderate to severe scalp psoriasis received placebo for risankizumab subcutaneously at Weeks 0 and 4 during Period A.

    Drug: Placebo for Risankizumab

  • Experimental
    Study-S Risankizumab (Period A)

    Participants with moderate to severe scalp psoriasis received 150 mg of risankizumab subcutaneously at Weeks 0 and 4 during Period A.

    Drug: Risankizumab

  • Experimental
    Study-G Placebo/Risankizumab (Period B)

    Participants with moderate to severe genital psoriasis received placebo for risankizumab during Period A, and 150 mg of risankizumab subcutaneously at Weeks 16, 28, and 40 during Period B.

    Drug: Risankizumab

  • Experimental
    Study-G Risankizumab/Risankizumab (Period B)

    Participants with moderate to severe genital psoriasis received 150 mg of risankizumab subcutaneously during Period A, and continued with this treatment at Weeks 16, 28, and 40 during Period B.

    Drug: Risankizumab

  • Experimental
    Study-S Placebo/Risankizumab (Period B)

    Participants with moderate to severe scalp psoriasis received placebo for risankizumab during Period A, and 150 mg of risankizumab subcutaneously at Weeks 16, 28, and 40 during Period B.

    Drug: Risankizumab

  • Experimental
    Study-S Risankizumab/Risankizumab (Period B)

    Participants with moderate to severe scalp psoriasis received 150 mg of risankizumab subcutaneously during Period A, and continued with this treatment at Weeks 16, 28, and 40 during Period B.

    Drug: Risankizumab

Interventions

  • Subcutaneous injection

    Also known as: Skyrizi, ABBV-066

  • DrugPlacebo for Risankizumab

    Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 or 1 at Week 16

    The sPGA-G is a 6-point score ranging from 0 to 5, with a higher score indicating greater severity, based on the physician's assessment of the average thickness, erythema, and scaling of psoriatic genital lesions.

    Time frame: Week 16

  2. Study-S: Percentage of Participants With Achievement of Scalp Investigator Global Assessment (IGA) of 0 or 1 at Week 16

    The scalp IGA is a measurement of overall scalp involvement by the investigator at the time of evaluation. The scalp IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, scaling, and plaque elevation. Higher scores indicate more severe disease.

    Time frame: Week 16

Secondary outcomes

  1. Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 at Week 16

    The sPGA-G is a 6-point score ranging from 0 to 5, with a higher score indicating greater severity, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions.

    Time frame: Week 16

  2. Study-G: Percentage of Participants With Achievement of Dermatology Life Quality Index (DLQI) of 0 or 1 at Week 16

    The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, treatment) and has a 1-week recall period. The response options range from 0 (not affected at all) to 3 (very much affected). This gives an overall range of 0 to 30 where lower scores mean better quality of life.

    Time frame: Week 16

  3. Study-G: Percentage of Participants With Achievement of Clinically Meaningful (≥ 4-point) Improvement From Baseline on the Genital Psoriasis Itch Numerical Rating Scale (NRS) at Week 16 [Among Participants With a Baseline Score ≥ 4]

    The scalp Itch NRS is a self-administered NRS that asks participants to assess their scalp itch on a scale from 0 to 10 where 0 represents no itch and 10 represents worst imaginable itch.

    Time frame: Baseline, Week 16

  4. Study-G: Percentage of Participants With Achievement of Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16 [Among Participants With a Baseline Score ≥ 2]

    The GenPs-SFQ is a patient-reported outcome(s) \[PRO\] measure to evaluate the impact of genital psoriasis symptoms on sexual frequency, using a 1-week recall period. It consists of 2 items that assess the impact of genital psoriasis symptoms on the frequency of sexual activity. Each item uses a Likert scale. Respondents are asked to answer the questions based on their psoriasis symptoms in the genital area. Genital area is defined as the labia majora (outer lip), labia minora (inner lip), and perineum (area between vagina and anus) for females; penis, scrotum, and perineum (area between the penis and anus) for males. Item 2 assesses how often genital psoriasis symptoms limited the frequency of sexual activity with response options ranging from 0 (never) to 4 (always).

    Time frame: Baseline, Week 16

  5. Study-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index 90 (PSSI 90) at Week 16

    PSSI 90 is defined as ≥ 90% improvement from Baseline in PSSI. The physician will assess the severity of scalp psoriasis using the PSSI, which consists of an assessment of erythema, induration, and desquamation on a scale from 0 (none) to 4 (very severe) and the percentage of scalp involved on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is calculated as the sum of the scores for erythema, induration and desquamation multiplied by the score recorded for the extent of scalp area involved. The PSSI ranges from 0 to 72, with higher scores indicating more severe disease.

    Time frame: Baseline, Week 16

  6. Study-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index 75 (PSSI 75) at Week 16

    PSSI 75 is defined as ≥ 75% improvement from Baseline in PSSI. The physician will assess the severity of scalp psoriasis using the PSSI, which consists of an assessment of erythema, induration, and desquamation on a scale from 0 (none) to 4 (very severe) and the percentage of scalp involved on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is calculated as the sum of the scores for erythema, induration and desquamation multiplied by the score recorded for the extent of scalp area involved. The PSSI ranges from 0 to 72, with higher scores indicating more severe disease.

    Time frame: Baseline, Week 16

  7. Study-S: Change From Baseline in Psoriasis Symptom Scale (PSS) at Week 16

    The PSS is a 4-item PRO instrument that assesses the severity of psoriasis symptoms in participants with moderate to severe psoriasis, using a recall period of 1 day. The symptoms include pain, redness, itching and burning from psoriasis. Current symptom severity is assessed using a 5-point Likert-type scale ranging from 0 (none) to 4 (very severe), with total scores, which is the sum of the four item responses, ranging from 0 to 16 and higher scores indicating worse symptoms. Negative changes from Baseline indicate improvement.

    Time frame: Baseline, Week 16

  8. Study-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index (PSSI 100) at Week 16

    PSSI 100 is defined as ≥ 100% improvement from Baseline in PSSI. The physician will assess the severity of scalp psoriasis using the PSSI, which consists of an assessment of erythema, induration, and desquamation on a scale from 0 (none) to 4 (very severe) and the percentage of scalp involved on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is calculated as the sum of the scores for erythema, induration and desquamation multiplied by the score recorded for the extent of scalp area involved. The PSSI ranges from 0 to 72, with higher scores indicating more severe disease.

    Time frame: Baseline, Week 16

  9. Study-S: Percentage of Participants With Achievement of Psoriasis Symptom Scale (PSS) of 0 at Week 16

    The PSS is a 4-item PRO instrument that assesses the severity of psoriasis symptoms in participants with moderate to severe psoriasis, using a recall period of 1 day. The symptoms include pain, redness, itching and burning from psoriasis. Current symptom severity is assessed using a 5-point Likert-type scale ranging from 0 (none) to 4 (very severe).

    Time frame: Week 16

07

Results

Posted Feb 24, 2026

Participant flow

This study was conducted at 30 sites in the United States with a total of 214 participants and was initiated in August 2023. Adults with with moderate to severe genital (Study-G) or scalp (Study-S) psoriasis were eligible.

Period A (Week 0-16)
Participant flow — Period A (Week 0-16)
MilestoneStudy-G Placebo (Period A)Study-G Risankizumab (Period A)Study-S Placebo (Period A)Study-S Risankizumab (Period A)Study-G Placebo/Risankizumab (Period B)Study-G Risankizumab/Risankizumab (Period B)Study-S Placebo/Risankizumab (Period B)Study-S Risankizumab/Risankizumab (Period B)
Started545554510000
Completed535449510000
Not completed11500000
Withdrew: Lost to follow-up10200000
Withdrew: Other, not specified01000000
Withdrew: Withdrawal by subject00300000
Period B (Week 16-52)
Participant flow — Period B (Week 16-52)
MilestoneStudy-G Placebo (Period A)Study-G Risankizumab (Period A)Study-S Placebo (Period A)Study-S Risankizumab (Period A)Study-G Placebo/Risankizumab (Period B)Study-G Risankizumab/Risankizumab (Period B)Study-S Placebo/Risankizumab (Period B)Study-S Risankizumab/Risankizumab (Period B)
Started000053544851
Completed00001191719
Not completed000042453132
Withdrew: Withdrawal by subject00002016
Withdrew: Lost to follow-up00000030
Withdrew: Other, not specified00000001
Withdrew: Ongoing in period b000040452725

Outcome measures

PrimaryStudy-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 or 1 at Week 16

The sPGA-G is a 6-point score ranging from 0 to 5, with a higher score indicating greater severity, based on the physician's assessment of the average thickness, erythema, and scaling of psoriatic genital lesions.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 or 1 at Week 16
percentage of participantsStudy-G Placebo (Period A)Study-G Risankizumab (Period A)
Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 or 1 at Week 1613.069.1
Statistical analysis
  • Study-G Placebo (Period A) vs Study-G Risankizumab (Period A) · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 57.0 · 95% CI 42.3 to 71.7Study-G Risankizumab (Period A) - Study-G Placebo (Period A)
PrimaryStudy-S: Percentage of Participants With Achievement of Scalp Investigator Global Assessment (IGA) of 0 or 1 at Week 16

The scalp IGA is a measurement of overall scalp involvement by the investigator at the time of evaluation. The scalp IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, scaling, and plaque elevation. Higher scores indicate more severe disease.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Study-S: Percentage of Participants With Achievement of Scalp Investigator Global Assessment (IGA) of 0 or 1 at Week 16
percentage of participantsStudy-S Placebo (Period A)Study-S Risankizumab (Period A)
Study-S: Percentage of Participants With Achievement of Scalp Investigator Global Assessment (IGA) of 0 or 1 at Week 1613.0 (4.0 to 21.9)60.8 (47.4 to 74.2)
Statistical analysis
  • Study-S Placebo (Period A) vs Study-S Risankizumab (Period A) · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 47.0 · 95% CI 31.2 to 62.8Study-S Risankizumab (Period A) - Study-S Placebo (Period A)
SecondaryStudy-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 at Week 16

The sPGA-G is a 6-point score ranging from 0 to 5, with a higher score indicating greater severity, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 at Week 16
percentage of participantsStudy-G Placebo (Period A)Study-G Risankizumab (Period A)
Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 at Week 165.6 (0.0 to 11.7)50.9 (37.7 to 64.1)
Statistical analysis
  • Study-G Placebo (Period A) vs Study-G Risankizumab (Period A) · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 46.7 · 95% CI 32.6 to 60.8Study-G Risankizumab (Period A) - Study-G Placebo (Period A)
SecondaryStudy-G: Percentage of Participants With Achievement of Dermatology Life Quality Index (DLQI) of 0 or 1 at Week 16

The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, treatment) and has a 1-week recall period. The response options range from 0 (not affected at all) to 3 (very much affected). This gives an overall range of 0 to 30 where lower scores mean better quality of life.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Study-G: Percentage of Participants With Achievement of Dermatology Life Quality Index (DLQI) of 0 or 1 at Week 16
percentage of participantsStudy-G Placebo (Period A)Study-G Risankizumab (Period A)
Study-G: Percentage of Participants With Achievement of Dermatology Life Quality Index (DLQI) of 0 or 1 at Week 163.7 (0.0 to 8.7)60.0 (47.1 to 72.9)
Statistical analysis
  • Study-G Placebo (Period A) vs Study-G Risankizumab (Period A) · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 56.5 · 95% CI 43.0 to 70.0Study-G Risankizumab (Period A) - Study-G Placebo (Period A)
SecondaryStudy-G: Percentage of Participants With Achievement of Clinically Meaningful (≥ 4-point) Improvement From Baseline on the Genital Psoriasis Itch Numerical Rating Scale (NRS) at Week 16 [Among Participants With a Baseline Score ≥ 4]

The scalp Itch NRS is a self-administered NRS that asks participants to assess their scalp itch on a scale from 0 to 10 where 0 represents no itch and 10 represents worst imaginable itch.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Study-G: Percentage of Participants With Achievement of Clinically Meaningful (≥ 4-point) Improvement From Baseline on the Genital Psoriasis Itch Numerical Rating Scale (NRS) at Week 16 [Among Participants With a Baseline Score ≥ 4]
percentage of participantsStudy-G Placebo (Period A)Study-G Risankizumab (Period A)
Study-G: Percentage of Participants With Achievement of Clinically Meaningful (≥ 4-point) Improvement From Baseline on the Genital Psoriasis Itch Numerical Rating Scale (NRS) at Week 16 [Among Participants With a Baseline Score ≥ 4]6.7 (0.0 to 14.0)48.8 (33.5 to 64.1)
Statistical analysis
  • Study-G Placebo (Period A) vs Study-G Risankizumab (Period A) · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 43.0 · 95% CI 26.6 to 59.3Study-G Risankizumab (Period A) - Study-G Placebo (Period A)
SecondaryStudy-G: Percentage of Participants With Achievement of Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16 [Among Participants With a Baseline Score ≥ 2]

The GenPs-SFQ is a patient-reported outcome(s) \[PRO\] measure to evaluate the impact of genital psoriasis symptoms on sexual frequency, using a 1-week recall period. It consists of 2 items that assess the impact of genital psoriasis symptoms on the frequency of sexual activity. Each item uses a Likert scale. Respondents are asked to answer the questions based on their psoriasis symptoms in the genital area. Genital area is defined as the labia majora (outer lip), labia minora (inner lip), and perineum (area between vagina and anus) for females; penis, scrotum, and perineum (area between the penis and anus) for males. Item 2 assesses how often genital psoriasis symptoms limited the frequency of sexual activity with response options ranging from 0 (never) to 4 (always).

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Study-G: Percentage of Participants With Achievement of Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16 [Among Participants With a Baseline Score ≥ 2]
percentage of participantsStudy-G Placebo (Period A)Study-G Risankizumab (Period A)
Study-G: Percentage of Participants With Achievement of Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16 [Among Participants With a Baseline Score ≥ 2]21.9 (7.6 to 36.2)71.0 (55.0 to 86.9)
Statistical analysis
  • Study-G Placebo (Period A) vs Study-G Risankizumab (Period A) · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 46.1 · 95% CI 26.7 to 65.6Study-G Risankizumab (Period A) - Study-G Placebo (Period A)
SecondaryStudy-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index 90 (PSSI 90) at Week 16

PSSI 90 is defined as ≥ 90% improvement from Baseline in PSSI. The physician will assess the severity of scalp psoriasis using the PSSI, which consists of an assessment of erythema, induration, and desquamation on a scale from 0 (none) to 4 (very severe) and the percentage of scalp involved on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is calculated as the sum of the scores for erythema, induration and desquamation multiplied by the score recorded for the extent of scalp area involved. The PSSI ranges from 0 to 72, with higher scores indicating more severe disease.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Study-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index 90 (PSSI 90) at Week 16
percentage of participantsStudy-S Placebo (Period A)Study-S Risankizumab (Period A)
Study-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index 90 (PSSI 90) at Week 1613.0 (4.0 to 21.9)52.9 (39.2 to 66.6)
Statistical analysis
  • Study-S Placebo (Period A) vs Study-S Risankizumab (Period A) · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 39.8 · 95% CI 24.4 to 55.2Study-S Risankizumab (Period A) - Study-S Placebo (Period A)
SecondaryStudy-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index 75 (PSSI 75) at Week 16

PSSI 75 is defined as ≥ 75% improvement from Baseline in PSSI. The physician will assess the severity of scalp psoriasis using the PSSI, which consists of an assessment of erythema, induration, and desquamation on a scale from 0 (none) to 4 (very severe) and the percentage of scalp involved on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is calculated as the sum of the scores for erythema, induration and desquamation multiplied by the score recorded for the extent of scalp area involved. The PSSI ranges from 0 to 72, with higher scores indicating more severe disease.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Study-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index 75 (PSSI 75) at Week 16
percentage of participantsStudy-S Placebo (Period A)Study-S Risankizumab (Period A)
Study-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index 75 (PSSI 75) at Week 1622.2 (11.1 to 33.3)74.5 (62.5 to 86.5)
Statistical analysis
  • Study-S Placebo (Period A) vs Study-S Risankizumab (Period A) · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 52.9 · 95% CI 37.5 to 68.3Study-S Risankizumab (Period A) - Study-S Placebo (Period A)
SecondaryStudy-S: Change From Baseline in Psoriasis Symptom Scale (PSS) at Week 16

The PSS is a 4-item PRO instrument that assesses the severity of psoriasis symptoms in participants with moderate to severe psoriasis, using a recall period of 1 day. The symptoms include pain, redness, itching and burning from psoriasis. Current symptom severity is assessed using a 5-point Likert-type scale ranging from 0 (none) to 4 (very severe), with total scores, which is the sum of the four item responses, ranging from 0 to 16 and higher scores indicating worse symptoms. Negative changes from Baseline indicate improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Study-S: Change From Baseline in Psoriasis Symptom Scale (PSS) at Week 16
units on a scaleStudy-S Placebo (Period A)Study-S Risankizumab (Period A)
Study-S: Change From Baseline in Psoriasis Symptom Scale (PSS) at Week 16-1.036 (-2.249 to 0.178)-6.013 (-7.283 to -4.743)
Statistical analysis
  • Study-S Placebo (Period A) vs Study-S Risankizumab (Period A) · Mixed Model for Repeated Measures (MMRM) · p = <0.0001 · Ls mean difference: -4.977 · 95% CI -6.615 to -3.340Study-S Risankizumab (Period A) - Study-S Placebo (Period A)
SecondaryStudy-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index (PSSI 100) at Week 16

PSSI 100 is defined as ≥ 100% improvement from Baseline in PSSI. The physician will assess the severity of scalp psoriasis using the PSSI, which consists of an assessment of erythema, induration, and desquamation on a scale from 0 (none) to 4 (very severe) and the percentage of scalp involved on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is calculated as the sum of the scores for erythema, induration and desquamation multiplied by the score recorded for the extent of scalp area involved. The PSSI ranges from 0 to 72, with higher scores indicating more severe disease.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Study-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index (PSSI 100) at Week 16
percentage of participantsStudy-S Placebo (Period A)Study-S Risankizumab (Period A)
Study-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index (PSSI 100) at Week 1613.0 (4.0 to 21.9)45.1 (31.4 to 58.8)
Statistical analysis
  • Study-S Placebo (Period A) vs Study-S Risankizumab (Period A) · Cochran-Mantel-Haenszel · p = =0.0001 · Response rate difference: 31.2 · 95% CI 15.4 to 46.9Study-S Risankizumab (Period A) - Study-S Placebo (Period A)
SecondaryStudy-S: Percentage of Participants With Achievement of Psoriasis Symptom Scale (PSS) of 0 at Week 16

The PSS is a 4-item PRO instrument that assesses the severity of psoriasis symptoms in participants with moderate to severe psoriasis, using a recall period of 1 day. The symptoms include pain, redness, itching and burning from psoriasis. Current symptom severity is assessed using a 5-point Likert-type scale ranging from 0 (none) to 4 (very severe).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Study-S: Percentage of Participants With Achievement of Psoriasis Symptom Scale (PSS) of 0 at Week 16
percentage of participantsStudy-S Placebo (Period A)Study-S Risankizumab (Period A)
Study-S: Percentage of Participants With Achievement of Psoriasis Symptom Scale (PSS) of 0 at Week 163.7 (0.0 to 8.7)13.7 (4.3 to 23.2)
Statistical analysis
  • Study-S Placebo (Period A) vs Study-S Risankizumab (Period A) · Cochran-Mantel-Haenszel · p = =0.0539 · Response rate difference: 10.3 · 95% CI -0.2 to 20.7Study-S Risankizumab (Period A) - Study-S Placebo (Period A)

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from time informed consent was signed through 22 January 2025, after all participants completed Week 16 of Study-G or Study-S in Period A. Median time on follow-up in Period A was 112 days for all groups. Median time on follow-up in Period B ranged from 136 to 142 days in Study-G and 260 to 285 days in Study-S.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Study-G Placebo (Period A)0/54 (0%)1/54 (1.9%)8/54 (14.8%)
Study-G Risankizumab (Period A)0/55 (0%)1/55 (1.8%)8/55 (14.5%)
Study-S Placebo (Period A)0/54 (0%)1/54 (1.9%)7/54 (13%)
Study-S Risankizumab (Period A)0/51 (0%)3/51 (5.9%)9/51 (17.6%)
Study-G Placebo/Risankizumab (Period B)0/53 (0%)1/53 (1.9%)8/53 (15.1%)
Study-G Risankizumab/Risankizumab (Period B)0/54 (0%)1/54 (1.9%)8/54 (14.8%)
Study-S Placebo/Risankizumab (Period B)0/48 (0%)1/48 (2.1%)7/48 (14.6%)
Study-S Risankizumab/Risankizumab (Period B)0/51 (0%)3/51 (5.9%)9/51 (17.6%)
Most frequent serious events
Most frequent serious events
EventStudy-G Placebo (Period A)Study-G Risankizumab (Period A)Study-S Placebo (Period A)Study-S Risankizumab (Period A)Study-G Placebo/Risankizumab (Period B)Study-G Risankizumab/Risankizumab (Period B)Study-S Placebo/Risankizumab (Period B)Study-S Risankizumab/Risankizumab (Period B)
ACUTE MYOCARDIAL INFARCTIONCardiac disorders0/540/551/540/510/530/541/480/51
ANGINA UNSTABLECardiac disorders0/540/551/540/510/530/541/480/51
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders0/540/550/541/510/530/540/481/51
CELLULITISInfections and infestations0/541/550/541/510/531/540/481/51
ABORTION SPONTANEOUSPregnancy, puerperium and perinatal conditions0/540/550/541/510/530/540/481/51
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders1/540/550/540/511/530/540/480/51
Most frequent other events
Most frequent other events
EventStudy-G Placebo (Period A)Study-G Risankizumab (Period A)Study-S Placebo (Period A)Study-S Risankizumab (Period A)Study-G Placebo/Risankizumab (Period B)Study-G Risankizumab/Risankizumab (Period B)Study-S Placebo/Risankizumab (Period B)Study-S Risankizumab/Risankizumab (Period B)
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations2/544/552/546/512/534/542/486/51
COVID-19Infections and infestations2/542/552/544/512/532/542/484/51
NASOPHARYNGITISInfections and infestations2/542/553/541/512/532/543/481/51
DEPRESSIONPsychiatric disorders3/540/550/540/513/530/540/480/51

Baseline characteristics

Intent-to-Treat Population (ITT): ITT\_G (participants randomized in Study-G); ITT\_S (participants randomized in Study-S)

Age, Continuous
Age, Continuous(years)Study-G Placebo (Period A)Study-G Risankizumab (Period A)Study-S Placebo (Period A)Study-S Risankizumab (Period A)Total
Mean46.3 ± 15.7345.3 ± 14.9746.7 ± 14.2346.0 ± 14.7545.6 ± 14.80
Sex: Female, Male
Sex: Female, Male(Participants)Study-G Placebo (Period A)Study-G Risankizumab (Period A)Study-S Placebo (Period A)Study-S Risankizumab (Period A)Total
Female2216222484
Male32393227130
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Study-G Placebo (Period A)Study-G Risankizumab (Period A)Study-S Placebo (Period A)Study-S Risankizumab (Period A)Total
Hispanic or Latino1715261270
Not Hispanic or Latino37402839144
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Study-G Placebo (Period A)Study-G Risankizumab (Period A)Study-S Placebo (Period A)Study-S Risankizumab (Period A)Total
American Indian or Alaska Native00101
Asian13329
Native Hawaiian or Other Pacific Islander02002
Black or African American204410
White50484344185
More than one race12216
Unknown or Not Reported00101
08

Study locations

38 sites
  • Medical Dermatology Specialists /ID# 262915
    Phoenix, Arizona 85006, United States
  • Alliance Dermatology and Mohs Center /ID# 255846
    Phoenix, Arizona 85032, United States
  • Banner University Medicine Dermatology /ID# 255845
    Tucson, Arizona 85718-1407, United States
  • Private Practice - Dr. Tooraj Raoof /ID# 255334
    Encino, California 91436, United States
  • Dermatology Research Associates /ID# 255347
    Los Angeles, California 90045, United States
  • Clinical Trials Research Institute /ID# 264555
    Thousand Oaks, California 91320-2130, United States
  • Florida Academic Dermatology Center /ID# 264065
    Coral Gables, Florida 33134-5755, United States
  • Skin Care Research - Hollywood /ID# 255394
    Hollywood, Florida 33021-6748, United States
  • GSI Clinical Research, LLC /ID# 255472
    Margate, Florida 33063, United States
  • Skin and Cancer Associates, LLP /ID# 255506
    Miami, Florida 33137-3254, United States
  • Sullivan Dermatology /ID# 264067
    Miami, Florida 33162, United States
  • Renstar Medical Research /ID# 255339
    Ocala, Florida 34470, United States
  • Hamilton Research, LLC /ID# 255409
    Alpharetta, Georgia 30022, United States
  • Treasure Valley Medical Research /ID# 255671
    Boise, Idaho 83706, United States
  • DeNova Research /ID# 264063
    Chicago, Illinois 60610, United States
  • Arlington Dermatology /ID# 255330
    Rolling Meadows, Illinois 60008, United States
  • The Indiana Clinical Trials Center /ID# 255333
    Plainfield, Indiana 46168, United States
  • Dermatology Partners of Leawood /ID# 263244
    Leawood, Kansas 66211, United States
  • DermAssociates - Rockville /ID# 263252
    Rockville, Maryland 20850, United States
  • Skin Specialists /ID# 262929
    Omaha, Nebraska 68144, United States
  • Skin Cancer and Dermatology Institute (SCDI) /ID# 264570
    Sparks, Nevada 89436, United States
  • Care Access - Hoboken /ID# 264066
    Hoboken, New Jersey 07030, United States
  • Forest Hills Dermatology Group @ Union Turnpike /ID# 255346
    Kew Gardens, New York 11415, United States
  • Schweiger Dermatology, P.C. /ID# 255336
    New York, New York 07044-2946, United States
  • Darst Dermatology /ID# 255848
    Charlotte, North Carolina 28277, United States
  • Wright State Physicians Health Center /ID# 255395
    Fairborn, Ohio 45324, United States
  • Apex Clinical Research Center /ID# 263432
    Mayfield Heights, Ohio 44124, United States
  • Oregon Dermatology and Research Center /ID# 255670
    Portland, Oregon 97210, United States
  • Oregon Medical Research Center /ID# 255332
    Portland, Oregon 97239, United States
  • Studies in Dermatology LLC /ID# 262989
    Cypress, Texas 77429, United States
  • Modern Research Associates /ID# 263234
    Dallas, Texas 75231, United States
  • Center for Clinical Studies - Houston (Binz) /ID# 255396
    Houston, Texas 77004-8097, United States
  • U.S. Dermatology Partners Longview /ID# 266325
    Longview, Texas 75601, United States
  • Progressive Clinical Research - San Antonio /ID# 263255
    San Antonio, Texas 78229, United States
  • Center for Clinical Studies Webster TX /ID# 255518
    Webster, Texas 77598, United States
  • Care Access - Danville /ID# 266300
    Danville, Virginia 24541, United States
  • Center for Excellence in Dermatology /ID# 264647
    Kennewick, Washington 99336, United States
  • North Sound Dermatology /ID# 264565
    Mill Creek, Washington 98012, United States
09

References and documents

Publications

  • Song EJ, Ehst B, Glick B, Lewitt GM, Rich P, Ezra N, Bagel J, Anschutz T, Bialik B, Duan C, Ashley D, Patel M, St John G, Setty AR, Ackerman L. Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16. Dermatol Ther (Heidelb). 2026 Jan;16(1):293-307. doi: 10.1007/s13555-025-01544-6. Epub 2025 Oct 25. PubMed 41139175 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Jan 2025, 17 months.

Results were first posted in Feb 2026, 1 year 1 month after primary completion.

Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 17 months is below that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2023
First posted
Aug 1, 2023
StartActual
Aug 10, 2023
Primary completionActual
Jan 22, 2025
CompletionActual
Nov 28, 2025
Results first posted
Feb 24, 2026
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05969223
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Aug 10, 2023
Primary completion
Jan 22, 2025
Completion
Nov 28, 2025
Results posted
Feb 24, 2026
Last update
Feb 24, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion